Involvement of Interleukin 6 in Hepatitis B Viral Infection

Cellular Physiology and Biochemistry

Volumn 37, Issue 2, 2015, Pages 677-686

  Xia, Caixia ^a   Liu, Yanning ^a   Chen, Zhi ^a   Zheng, Min ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

HBx; Hepatitis B; Interleukin 6; SNP

Indexed keywords

AMINO ACID; INTERLEUKIN 6; IL6 PROTEIN, HUMAN;

ARTICLE; CHROMOSOME 7P; CHRONIC INFLAMMATION; CROHN DISEASE; CYTOKINE PRODUCTION; DISEASE COURSE; GENE LOCATION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; NONHUMAN; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; UPREGULATION; VIRUS ENTRY; VIRUS REPLICATION; FEMALE; GENE EXPRESSION REGULATION; GENETICS; MALE; METABOLISM; PHYSIOLOGY; SINGLE NUCLEOTIDE POLYMORPHISM; VIROLOGY;

DISEASE PROGRESSION; FEMALE; GENE EXPRESSION REGULATION; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; INTERLEUKIN-6; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; VIRUS REPLICATION;

EID: 84941247594     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000430386     Document Type: Article

References (77)

1. Wright TL, Lau JYN: Clinical aspects of hepatitis-b virus-infection. Lancet 1993;342:1340-1344.
2. Chisari FV, Ferrari C: Hepatitis-b virus immunopathogenesis. Annu Rev Immunol 1995;13:29-60.
3. Balmasova IP, Yushchuk ND, Mynbaev OA, Alla NR, Malova ES, Shi Z, Gao CL: Immunopathogenesis of chronic hepatitis b. World J Gastroenterol 2014;20:14156-14171.
4. Li X, Liu X, Tian L, Chen Y: Cytokine-mediated immunopathogenesis of hepatitis b virus infections. Clin Rev Allergy Immunol DOI:10.1007/s12016-014-8465-4.
5. Akpolat N, Yahsi S, Godekmerdan A, Demirbag K, Yalniz M: Relationship between serum cytokine levels and histopathological changes of liver in patients with hepatitis b. World J Gastroenterol 2005;11:3260-3263.
6. Burger R: Impact of interleukin-6 in hematological malignancies. Transfus Med Hemother 2013;40:336-343.
7. Rincon M, Irvin CG: Role of il-6 in asthma and other inflammatory pulmonary diseases. Int J Biol Sci 2012;8:1281-1290.
8. Mihara M, Hashizume M, Yoshida H, Suzuki M, Shiina M: Il-6/il-6 receptor system and its role in physiological and pathological conditions. Clin Sci (Lond) 2012;122:143-159.
9. Scheller J, Chalaris A, Schmidt-Arras D, Rose-John S: The pro-and anti-inflammatory properties of the cytokine interleukin-6. Biochim Biophys Acta 2011;1813:878-888.
10. Muller-Newen G, Kohne C, Keul R, Hemmann U, Muller-Esterl W, Wijdenes J, Brakenhoff JP, Hart MH, Heinrich PC: Purification and characterization of the soluble interleukin-6 receptor from human plasma and identification of an isoform generated through alternative splicing. Eur J Biochem 1996;236:837-842.
11. Sun R, Tian Z, Kulkarni S, Gao B: Il-6 prevents t cell-mediated hepatitis via inhibition of nkt cells in cd4+ t cell-and stat3-dependent manners. J Immunol 2004;172:5648-5655.
12. Rose-John S: Il-6 trans-signaling via the soluble il-6 receptor: Importance for the pro-inflammatory activities of il-6. Int J Biol Sci 2012;8:1237-1247.
13. Tanaka T, Kishimoto T: The biology and medical implications of interleukin-6. Cancer Immunol Res 2014;2:288-294.
14. Luo MX, Wong SH, Chan MT, Yu L, Yu SS, Wu F, Xiao Z, Wang X, Zhang L, Cheng AS, Ng SS, Chan FK, Cho CH, Yu J, Sung JJ, Wu WK: Autophagy mediates hbx-induced nuclear factor-kappab activation and release of il-6, il-8, and cxcl2 in hepatocytes. J Cell Physiol 2015;230:2382-2389.
15. Alison MR, Nicholson LJ, Lin WR: Chronic inflammation and hepatocellular carcinoma. Recent Results Cancer Res 2011;185:135-148.
16. Kumar H, Kawai T, Akira S: Pathogen recognition by the innate immune system. Int Rev Immunol 2011;30:16-34.
17. Bianchi ME: Damps, pamps and alarmins: All we need to know about danger. J Leukocyte Biol 2007;81:1-5.
18. Yang Y, Li S, Yang Q, Shi Y, Zheng M, Liu Y, Chen F, Song G, Xu H, Wan T, He J, Chen Z: Resveratrol reduces the proinflammatory effects and lipopolysaccharide-induced expression of hmgb1 and tlr4 in raw264.7 cells. Cell Physiol Biochem 2014;33:1283-1292.
19. Song le H, Binh VQ, Duy DN, Kun JF, Bock TC, Kremsner PG, Luty AJ: Serum cytokine profiles associated with clinical presentation in vietnamese infected with hepatitis b virus. J Clin Virol 2003;28:93-103.
20. Zhang F, Yao S, Zhang M, Yuan J, Chen X, Zhou B: Roles of circulating soluble interleukin (il)-6 receptor and il-6 receptor expression on cd4+ t cells in patients with chronic hepatitis b. Int J Infect Dis 2011;15:e267-271.
21. Tang S, Liu Z, Zhang Y, He Y, Pan D, Liu Y, Liu Q, Zhang Z, Yuan Y: Rather than rs1800796 polymorphism, expression of interleukin-6 is associated with disease progression of chronic hbv infection in a chinese han population. Dis Markers 2013;35:799-805.
22. Pan CJ, Wu HL, Kuo SF, Kao JH, Tseng TC, Liu CH, Chen PJ, Liu CJ, Chen DS: Serum interleukin 6 level correlates with outcomes of acute exacerbation of chronic hepatitis b. Hepatol Int 2012;6:591-597.
23. Liaw YF: Hbeag seroconversion as an important end point in the treatment of chronic hepatitis b. Hepatol Int 2009;3:425-433.
24. Wu HL, Kao JH, Chen TC, Wu WH, Liu CH, Su TH, Yang HC, Chen DS, Chen PJ, Liu CJ: Serum cytokine/ chemokine profiles in acute exacerbation of chronic hepatitis b: Clinical and mechanistic implications. J Gastroenterol Hepatol 2014;29:1629-1636.
25. Tanaka T, Narazaki M, Ogata A, Kishimoto T: A new era for the treatment of inflammatory autoimmune diseases by interleukin-6 blockade strategy. Semin Immunol 2014;26:88-96.
26. Toshio Tanaka MN, Kazuya Masuda, Tadamitsu Kishimoto: Interleukin-6; pathogenesis and treatment of autoimmune inflammatory diseases. Inflamm Regen 2013;33:54-65.
27. Kong HJ, Nam BH, Kim YO, Kim WJ, Cho HK, Lee CH, Lee SJ, Kim KK: Characterization of the flounder il-6 promoter and its regulation by the p65 nf-kappab subunit. Fish Shellfish Immunol 2010;28:961-964.
28. Hu Y, Xue J, Yang Y, Zhou X, Qin C, Zheng M, Zhu H, Liu Y, Liu W, Lou G, Wang J, Wu S, Chen Z, Chen F: Lipocalin 2 upregulation protects hepatocytes from il1-beta-induced stress. Cell Physiol Biochem 2015;36:753-762.
29. Lu H, Zhou J: Hbv x gene transfection upregulates il-1beta and il-6 gene expression and induces rat glomerular mesangial cell proliferation. J Huazhong Univ Sci Technolog Med Sci 2008;28:247-250.
30. Quetier I, Brezillon N, Duriez M, Massinet H, Giang E, Ahodantin J, Lamant C, Brunelle MN, Soussan P, Kremsdorf D: Hepatitis b virus hbx protein impairs liver regeneration through enhanced expression of il-6 in transgenic mice. J Hepatol 2013;59:285-291.
31. Xiang WQ, Feng WF, Ke W, Sun Z, Chen Z, Liu W: Hepatitis b virus x protein stimulates il-6 expression in hepatocytes via a myd88-dependent pathway. J Hepatol 2011;54:26-33.
32. Prieto J: Inflammation, hcc and sex: Il-6 in the centre of the triangle. J Hepatol 2008;48:380-381.
33. Karin M, Greten FR: Nf-kappab: Linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 2005;5:749-759.
34. Berasain C, Castillo J, Perugorria MJ, Latasa MU, Prieto J, Avila MA: Inflammation and liver cancer: New molecular links. Ann N Y Acad Sci 2009;1155:206-221.
35. Naugler WE, Sakurai T, Kim S, Maeda S, Kim K, Elsharkawy AM, Karin M: Gender disparity in liver cancer due to sex differences in myd88-dependent il-6 production. Science 2007;317:121-124.
36. Chang TS, Wu YC, Chi CC, Su WC, Chang PJ, Lee KF, Tung TH, Wang J, Liu JJ, Tung SY, Kuo LM, Ho HN, Ling TY, Huang YH: Activation of il6/igfir confers poor prognosis of hbv-related hepatocellular carcinoma through induction of oct4/nanog expression. Clin Cancer Res 2015;21:201-210.
37. Yang XR, Xu Y, Yu B, Zhou J, Qiu SJ, Shi GM, Zhang BH, Wu WZ, Shi YH, Wu B, Yang GH, Ji Y, Fan J: High expression levels of putative hepatic stem/progenitor cell biomarkers related to tumour angiogenesis and poor prognosis of hepatocellular carcinoma. Gut 2010;59:953-962.
38. Li CH, Xu FY, Chow S, Feng L, Yin DL, Ng TB, Chen YC: Hepatitis b virus x protein promotes hepatocellular carcinoma transformation through interleukin-6 activation of microrna-21 expression. Eur J Cancer 2014;50:2560-2569.
39. Galun E, Nahor O, Eid A, Jurim O, Rose-John S, Blum HE, Nussbaum O, Ilan E, Daudi N, Shouval D, Reisner Y, Dagan S: Human interleukin-6 facilitates hepatitis b virus infection in vitro and in vivo. Virology 2000;270:299-309.
40. Bouezzedine F, Fardel O, Gripon P: Interleukin 6 inhibits hbv entry through ntcp down regulation. Virology 2015;481:34-42.
41. Kuo TM, Hu CP, Chen YL, Hong MH, Jeng KS, Liang CC, Chen ML, Chang C: Hbv replication is significantly reduced by il-6. J Biomed Sci 2009;16:41-49.
42. Zhao XM, Gao YF, Zhou Q, Pan FM, Li X: Relationship between interleukin-6 polymorphism and susceptibility to chronic hepatitis b virus infection. World J Gastroenterol 2013;19:6888-6893.
43. Urban S, Bartenschlager R, Kubitz R, Zoulim F: Strategies to inhibit entry of hbv and hdv into hepatocytes. Gastroenterology 2014;147:48-64.
44. Leistner CM, Gruen-Bernhard S, Glebe D: Role of glycosaminoglycans for binding and infection of hepatitis b virus. Cell Microbiol 2008;10:122-133.
45. Watashi K, Urban S, Li W, Wakita T: Ntcp and beyond: Opening the door to unveil hepatitis b virus entry. Int J Mol Sci 2014;15:2892-2905.
46. Huang HC, Chen CC, Chang WC, Tao MH, Huang C: Entry of hepatitis b virus into immortalized human primary hepatocytes by clathrin-dependent endocytosis. J Virol 2012;86:9443-9453.
47. Bremer CM, Sominskaya I, Skrastina D, Pumpens P, El Wahed AA, Beutling U, Frank R, Fritz HJ, Hunsmann G, Gerlich WH, Glebe D: N-terminal myristoylation-dependent masking of neutralizing epitopes in the pres1 attachment site of hepatitis b virus. J Hepatol 2011;55:29-37.
48. Neurath AR, Strick N, Sproul P: Search for hepatitis b virus cell receptors reveals binding sites for interleukin 6 on the virus envelope protein. J Exp Med 1992;175:461-469.
49. Heinz D, Peters M, Prange R, Gerken G, Rose-John S: Possible role of human interleukin-6 and soluble interleukin-6 receptor in hepatitis b virus infection. J Viral Hepat 2001;8:186-193.
50. Yan H, Zhong G, Xu G, He W, Jing Z, Gao Z, Huang Y, Qi Y, Peng B, Wang H, Fu L, Song M, Chen P, Gao W, Ren B, Sun Y, Cai T, Feng X, Sui J, Li W: Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis b and d virus. Elife 2012;1:1-28.
51. Gripon P, Cannie I, Urban S: Efficient inhibition of hepatitis b virus infection by acylated peptides derived from the large viral surface protein. J Virol 2005;79:1613-1622.
52. Klein M, Thomas M, Hofmann U, Seehofer D, Damm G, Zanger UM: A systematic comparison of the impact of inflammatory signaling on absorption, distribution, metabolism, and excretion gene expression and activity in primary human hepatocytes and heparg cells. Drug Metab Dispos 2015;43:273-283.
53. Schulze A, Mills K, Weiss TS, Urban S: Hepatocyte polarization is essential for the productive entry of the hepatitis b virus. Hepatology 2012;55:373-383.
54. Lepere-Douard C, Trotard M, Le Seyec J, Gripon P: The first transmembrane domain of the hepatitis b virus large envelope protein is crucial for infectivity. J Virol 2009;83:11819-11829.
55. Lin SJ, Shu PY, Chang C, Ng AK, Hu CP: Il-4 suppresses the expression and the replication of hepatitis b virus in the hepatocellular carcinoma cell line hep3b. J Immunol 2003;171:4708-4716.
56. Chou YC, Chen ML, Hu CP, Chen YL, Chong CL, Tsai YL, Liu TL, Jeng KS, Chang C: Transforming growth factor-beta1 suppresses hepatitis b virus replication primarily through transcriptional inhibition of pregenomic rna. Hepatology 2007;46:672-681.
57. Wieland SF, Eustaquio A, Whitten-Bauer C, Boyd B, Chisari FV: Interferon prevents formation of replicationcompetent hepatitis b virus rna-containing nucleocapsids. Proc Natl Acad Sci U S A 2005;102:9913-9917.
58. Biermer M, Puro R, Schneider RJ: Tumor necrosis factor alpha inhibition of hepatitis b virus replication involves disruption of capsid integrity through activation of nf-kappab. J Virol 2003;77:4033-4042.
59. Hosel M, Quasdorff M, Wiegmann K, Webb D, Zedler U, Broxtermann M, Tedjokusumo R, Esser K, Arzberger S, Kirschning CJ, Langenkamp A, Falk C, Buning H, Rose-John S, Protzer U: Not interferon, but interleukin-6 controls early gene expression in hepatitis b virus infection. Hepatology 2009;50:1773-1782.
60. Chu CJ, Lok AS: Clinical significance of hepatitis b virus genotypes. Hepatology 2002;35:1274-1276.
61. Thursz M: Genetic susceptibility in chronic viral hepatitis. Antiviral Res 2001;52:113-116.
62. Giannitrapani L, Soresi M, Balasus D, Licata A, Montalto G: Genetic association of interleukin-6 polymorphism (-174 g/c) with chronic liver diseases and hepatocellular carcinoma. World J Gastroenterol 2013;19:2449-2455.
63. Park BL, Lee HS, Kim YJ, Kim JY, Jung JH, Kim LH, Shin HD: Association between interieukin 6 promoter variants and chronic hepatitis b progression. Exp Mol Med 2003;35:76-82.
64. Fedetz M, Matesanz F, Pascual M, Martin J, Fernandez O, Guerrero M, Alcina A: The-174/-597 promoter polymorphisms in the interleukin-6 gene are not associated with susceptibility to multiple sclerosis. J Neurol Sci 2001;190:69-72.
65. Migita K, Miyazoe S, Maeda Y, Daikoku M, Abiru S, Ueki T, Yano K, Nagaoka S, Matsumoto T, Nakao K, Hamasaki K, Yatsuhashi H, Ishibashi H, Eguchi K: Cytokine gene polymorphisms in japanese patients with hepatitis b virus infection-association between tgf-beta1 polymorphisms and hepatocellular carcinoma. J Hepatol 2005;42:505-510.
66. Ribeiro CS, Visentainer JE, Moliterno RA: Association of cytokine genetic polymorphism with hepatitis b infection evolution in adult patients. Mem Inst Oswaldo Cruz 2007;102:435-440.
67. Tang S, Yuan Y, He Y, Pan D, Zhang Y, Liu Y, Liu Q, Zhang Z, Liu Z: Genetic polymorphism of interleukin-6 influences susceptibility to hbv-related hepatocellular carcinoma in a male chinese han population. Hum Immunol 2014;75:297-301.
68. Lu Y, Peng J, Wang C, Zhu Y, Wang F, Sun Z: Il-6 promoter functional polymorphism-572c/g affects spontaneous clearance of hepatitis b virus infection. Clin Lab 2014;60:1903-1907.
69. Sato K, Tsuchiya M, Saldanha J, Koishihara Y, Ohsugi Y, Kishimoto T, Bendig MM: Reshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growth. Cancer Res 1993;53:851-856.
70. De Benedetti F, Brunner HI, Ruperto N, Kenwright A, Wright S, Calvo I, Cuttica R, Ravelli A, Schneider R, Woo P, Wouters C, Xavier R, Zemel L, Baildam E, Burgos-Vargas R, Dolezalova P, Garay SM, Merino R, Joos R, Grom A, Wulffraat N, Zuber Z, Zulian F, Lovell D, Martini A, Printo, Prcsg: Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med 2012;367:2385-2395.
71. Ogata A, Hirano T, Hishitani Y, Tanaka T: Safety and efficacy of tocilizumab for the treatment of rheumatoid arthritis. Clin Med Insights Arthritis Musculoskelet Disord 2012;5:27-42.
72. Nishimoto N, Kanakura Y, Aozasa K, Johkoh T, Nakamura M, Nakano S, Nakano N, Ikeda Y, Sasaki T, Nishioka K, Hara M, Taguchi H, Kimura Y, Kato Y, Asaoku H, Kumagai S, Kodama F, Nakahara H, Hagihara K, Yoshizaki K, Kishimoto T: Humanized anti-interleukin-6 receptor antibody treatment of multicentric castleman disease. Blood 2005;106:2627-2632.
73. Ogata A, Tanaka T: Tocilizumab for the treatment of rheumatoid arthritis and other systemic autoimmune diseases: Current perspectives and future directions. Int J Rheumatol 2012;2012:1-14.
74. Reijnders JG, Perquin MJ, Zhang N, Hansen BE, Janssen HL: Nucleos(t)ide analogues only induce temporary hepatitis b e antigen seroconversion in most patients with chronic hepatitis b. Gastroenterology 2010;139:491-498.
75. Walsh R, Locarnini S: Hepatitis b precore protein: Pathogenic potential and therapeutic promise. Yonsei Med J 2012;53:875-885.
76. Wang L, Zou ZQ, Liu CX, Liu XZ: Immunotherapeutic interventions in chronic hepatitis b virus infection: A review. J Immunol Methods 2014;407C:1-8.
77. Tanaka T, Narazaki M, Kishimoto T: Il-6 in inflammation, immunity, and disease. Cold Spring Harb Perspect Biol 2014;6:1-16.